Baudax orphan status for hemophilia A candidate

 Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

https://www.globenewswire.com/news-release/2023/09/28/2751180/0/en/Baudax-Bio-Announces-Orphan-Drug-Designation-Granted-by-U-S-FDA-for-TI-168-for-the-Treatment-of-Hemophilia-A-with-Inhibitors.html